Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

S. Gadgeel · SciRah

Researcher profile · Semantic Scholar

S. Gadgeel

Share profile

S. Gadgeel — researcher profile on SciRah

h-index: 77
Works: 569
Citations: 38K

Most-cited papers

Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRASG12C Mutation.
P. Jänne, Gregory Riely, S. Gadgeel, R. Heist +18 more
2022New England Journal of Medicine767 citations Open access
Semantic Scholar
Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non–Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study
M. Garassino, S. Gadgeel, G. Speranza, E. Felip +17 more
2023Journal of Clinical Oncology632 citations Open access
Semantic Scholar
Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC.
B. Cho, Shun Lu, E. Felip, A. Spira +53 more
2024New England Journal of Medicine403 citations Open access
Semantic Scholar
Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study
L. Paz-Ares, S. Champiat, W. Lai, H. Izumi +21 more
2023Journal of Clinical Oncology286 citations Open access
Semantic Scholar
Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non–Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations From a Phase 1/2 Trial
Gregory Riely, J. Neal, D. Camidge, A. Spira +18 more
2021Cancer Discovery167 citations Open access
Semantic Scholar
Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial
Solange Peters, R. Dziadziuszko, A. Morabito, E. Felip +22 more
2022Nature Medicine111 citations Open access
Semantic Scholar
Therapy for Stage IV Non–Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2023.3
I. Jaiyesimi, N. Leighl, Nofisat Ismaila, Krishna Alluri +20 more
2024Journal of Clinical Oncology66 citations
Semantic Scholar
Intracranial Efficacy of Adagrasib in Patients From the KRYSTAL-1 Trial With KRASG12C-Mutated Non–Small-Cell Lung Cancer Who Have Untreated CNS Metastases
M. Negrao, A. Spira, R. Heist, P. Jänne +8 more
2023Journal of Clinical Oncology66 citations Open access
Semantic Scholar
Selective Personalized RadioImmunotherapy for Locally Advanced Non–Small-Cell Lung Cancer Trial (SPRINT)
N. Ohri, S. Jolly, B. Cooper, R. Kabarriti +12 more
2023Journal of Clinical Oncology52 citations
Semantic Scholar
Practical management of adverse events in patients receiving tarlatamab, a delta‐like ligand 3–targeted bispecific T‐cell engager immunotherapy, for previously treated small cell lung cancer
Jacob M. Sands, S. Champiat, Horst-Dieter Hummel, Kelly Garneski Paulson +15 more
2024medRxiv50 citations Open access
Semantic Scholar
SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy
A. Drilon, Manish R Sharma, M. Johnson, T. Yap +21 more
2023Cancer Discovery48 citations Open access
Semantic Scholar
Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC
M. Garassino, S. Gadgeel, S. Novello, B. Halmos +17 more
2022JTO Clinical and Research Reports47 citations Open access
Semantic Scholar
Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2023.3
I. Jaiyesimi, N. Leighl, Nofisat Ismaila, Krishna Alluri +20 more
2024Journal of Clinical Oncology45 citations
Semantic Scholar
Comparison Between the 2021 USPSTF Lung Cancer Screening Criteria and Other Lung Cancer Screening Criteria for Racial Disparity in Eligibility.
Chang-Ye Pu, Christine M. Lusk, C. Neslund-Dudas, S. Gadgeel +2 more
2022JAMA Oncology45 citations Open access
Semantic Scholar
NVL-520 is a selective, TRK-sparing, and brain-penetrant inhibitor of ROS1 fusions and secondary resistance mutations
A. Drilon, J. Horan, A. Tangpeerachaikul, B. Besse +20 more
2022Cancer Discovery38 citations Open access
Semantic Scholar
Amivantamab compared with real-world therapies in patients with advanced non-small cell lung cancer harboring EGFR exon 20 insertion mutations who progressed after platinum-based chemotherapy.
A. Minchom, S. Viteri, L. Bazhenova, S. Gadgeel +8 more
2022Lung Cancer36 citations Open access
Semantic Scholar
Circulating Cell-free DNA as a Prognostic Biomarker in Patients with Advanced ALK+ Non–small Cell Lung Cancer in the Global Phase III ALEX Trial
R. Dziadziuszko, S. Peters, T. Mok, D. Camidge +9 more
2022Clinical Cancer Research36 citations Open access
Semantic Scholar
FP13.02 Pembrolizumab + Pemetrexed-Platinum vs Pemetrexed-Platinum for Metastatic NSCLC: 4-Year Follow-up From KEYNOTE-189
J. Gray, D. Rodríguez-Abreu, S. Powell, M. Hochmair +18 more
202136 citations Open access
Semantic Scholar
\zaAlectinib versus crizotinib in previously untreated ALK-positive advanced non-small cell lung cancer: Final overall survival analysis of the Phase III ALEX study.
S. Peters, R. Camidge, R. Dziadziuszko, S. Gadgeel +17 more
2025Annals of Oncology35 citations Open access
Semantic Scholar
MRTX-500 Phase 2 Trial: Sitravatinib With Nivolumab in Patients With Nonsquamous NSCLC Progressing On or After Checkpoint Inhibitor Therapy or Chemotherapy
K. He, D. Berz, S. Gadgeel, W. Iams +16 more
2023Journal of Thoracic Oncology34 citations Open access
Semantic Scholar
Pembrolizumab Plus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With Programmed Cell Death Ligand 1 Tumor Proportion Score Less Than 1%: Pooled Analysis of Outcomes After 5 Years of Follow-Up.
S. Gadgeel, D. Rodríguez-Abreu, B. Halmos, M. Garassino +6 more
2024Journal of Thoracic Oncology33 citations Open access
Semantic Scholar
KRYSTAL-1: Activity and safety of adagrasib (MRTX849) in patients with advanced/metastatic non–small cell lung cancer (NSCLC) harboring a KRASG12C mutation.
A. Spira, Gregory Riely, S. Gadgeel, R. Heist +16 more
2022Journal of Clinical Oncology30 citations
Semantic Scholar
973MO KEYNOTE-189 5-year update: First-line pembrolizumab (pembro) + pemetrexed (pem) and platinum vs placebo (pbo) + pem and platinum for metastatic nonsquamous NSCLC
M. Garassino, S. Gadgeel, G. Speranza, E. Felip +16 more
2022Annals of Oncology26 citations Open access
Semantic Scholar
Fast progression in non–small cell lung cancer: results from the randomized phase III OAK study evaluating second-line atezolizumab versus docetaxel
D. Gandara, M. Reck, D. Moro-Sibilot, J. Mazières +7 more
2021Journal for ImmunoTherapy of Cancer23 citations Open access
Semantic Scholar
A Phase II Trial of Pevonedistat and Docetaxel in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer.
A. Qin, Leah E. Wells, B. Malhotra, S. Gadgeel +4 more
2023Clinical Lung Cancer21 citations
Semantic Scholar
Comparison of SP142 and 22C3 Immunohistochemistry PD-L1 Assays for Clinical Efficacy of Atezolizumab in Non-Small Cell Lung Cancer: Results From the Randomized OAK Trial.
S. Gadgeel, F. Hirsch, K. Kerr, F. Barlesi +12 more
2021Clinical Lung Cancer21 citations Open access
Semantic Scholar
Comparative Clinical Outcomes Between EGFR Ex20ins and Wildtype NSCLC Treated with Immune Checkpoint Inhibitors.
N. Girard, A. Minchom, S. Ou, S. Gadgeel +6 more
2022Clinical Lung Cancer20 citations Open access
Semantic Scholar
A phase 1/2 study of REGN5093-M114, a METxMET antibody-drug conjugate, in patients with mesenchymal epithelial transition factor (MET)-overexpressing NSCLC.
A. Drilon, M. Awad, S. Gadgeel, Liza C. Villaruz +9 more
2022Journal of Clinical Oncology20 citations
Semantic Scholar
Brief Report: Safety and Antitumor Activity of Alectinib Plus Atezolizumab From a Phase 1b Study in Advanced ALK-Positive NSCLC
Dong-Wan Kim, S. Gadgeel, S. Gettinger, Gregory Riely +10 more
2022JTO Clinical and Research Reports20 citations Open access
Semantic Scholar
Continuation of Lorlatinib in ALK-positive NSCLC Beyond Progressive Disease.
S. Ou, B. Solomon, A. Shaw, S. Gadgeel +6 more
2022Journal of Thoracic Oncology15 citations Open access
Semantic Scholar
Amivantamab plus lazertinib vs osimertinib in first-line EGFR-mutant advanced non-small cell lung cancer (NSCLC) with biomarkers of high-risk disease: A secondary analysis from the phase 3 MARIPOSA study.
E. Felip, B. C. Cho, Vanesa Gutiérrez, A. Alip +16 more
2024Journal of Clinical Oncology14 citations
Semantic Scholar
Pembrolizumab with platinum-based chemotherapy with or without epacadostat as first-line treatment for metastatic non-small cell lung cancer: a randomized, partially double-blind, placebo-controlled phase II study
M. Boyer, R. Hui, Damien Urban, P. Clingan +10 more
2024BMC Cancer12 citations Open access
Semantic Scholar
Abstract CT229: CRESTONE: A Phase 2 study of seribantumab in adult patients with neuregulin-1 (NRG1) fusion positive locally advanced or metastatic solid tumors
T. Patil, D. Carrizosa, M. Burkard, K. Reckamp +11 more
2023Cancer Research12 citations
Semantic Scholar
Safety and efficacy of D-1553 in KRAS G12C-mutated colorectal cancer: Results from a phase I/II study.
D. Ruan, M. Lee, Yan-Hong Deng, Keun-Wook Lee +15 more
2023Journal of Clinical Oncology12 citations Open access
Semantic Scholar
Phase II study of docetaxel and trametinib in patients with KRAS mutation positive recurrent non-small cell lung cancer (NSCLC) (SWOG S1507, NCT-02642042)
S. Gadgeel, Jieling Miao, J. Riess, J. Moon +11 more
2023Clinical Cancer Research12 citations Open access
Semantic Scholar
Safety of pemetrexed plus platinum in combination with pembrolizumab for metastatic nonsquamous non-small cell lung cancer: A post hoc analysis of KEYNOTE-189.
E. Garon, J. Aerts, J. S. Kim, C. Muehlenbein +3 more
2021Lung Cancer12 citations Open access
Semantic Scholar
Beyond Checkpoint Inhibitors: Enhancing Antitumor Immune Response in Lung Cancer.
R. Sanborn, F. Schneiders, S. Senan, S. Gadgeel
2022American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting11 citations Open access
Semantic Scholar
Lung Carcinoid Tumors with Potentially Actionable Genomic Alterations and Responses to Targeted Therapies
S. Waliany, Y.P. Hung, F. Rous, Faustine X Luo +10 more
2025Clinical Lung Cancer10 citations
Semantic Scholar
Brief Report on Use of Pembrolizumab With or Without Chemotherapy for Advanced Lung Cancer: A Real-World Analysis.
M. Izano, C. Sweetnam, Chenan Zhang, J. Weese +9 more
2023Clinical Lung Cancer10 citations Open access
Semantic Scholar
Cancer is chronic but antimicrobial stewardship is iconic: A retrospective cohort of optimal antibiotic use in ambulatory oncology clinics
Tiffany A. Ho, Katelyn M. Patterson, S. Gadgeel, Rachel M. Kenney +1 more
2023Antimicrobial Stewardship and Healthcare Epidemiology10 citations Open access
Semantic Scholar
Rapid real‐world data analysis of patients with cancer, with and without COVID‐19, across distinct health systems
C. Hwang, M. Izano, M. Thompson, S. Gadgeel +11 more
2021Cancer Reports10 citations Open access
Semantic Scholar
Phase I Study of Glesatinib (MGCD265) in Combination with Erlotinib or Docetaxel in Patients with Advanced Solid Tumors
A. Patnaik, S. Gadgeel, K. Papadopoulos, D. Rasco +8 more
2022Targeted oncology9 citations
Semantic Scholar
Assessing a Polygenic Risk Score for Lung Cancer Susceptibility in Non-Hispanic White and Black Populations
Matthew R. Trendowski, Christine M. Lusk, A. Wenzlaff, C. Neslund-Dudas +3 more
2023Cancer Epidemiology, Biomarkers and Prevention8 citations Open access
Semantic Scholar
The Selective Personalized Radio-immunotherapy for Locally Advanced NSCLC Trial (SPRINT): Initial results.
N. Ohri, S. Jolly, B. Cooper, R. Kabarriti +11 more
2022Journal of Clinical Oncology8 citations
Semantic Scholar
Pemetrexed and Platinum Plus Pembrolizumab in Patients With Metastatic Nonsquamous NSCLC by Tumor Burden at Baseline: A Post Hoc Efficacy Analysis of KEYNOTE-189
S. Gadgeel, J. Gray, M. T. Rizzo, P. Peterson +2 more
2022JTO Clinical and Research Reports8 citations Open access
Semantic Scholar
RAMP 202: A phase 2 study of avutometinib (VS-6766) ± defactinib, in patients with advanced KRAS G12V mutant non–small cell lung cancer (NSCLC).
J. Reuss, S. Gandhi, D. Spigel, P. Janne +14 more
2023Journal of Clinical Oncology7 citations
Semantic Scholar
A phase 1/2 study of the highly selective EGFR inhibitor, BLU-701, in patients with EGFR-mutant non–small cell lung cancer (NSCLC).
A. Spira, D. Spigel, D. Camidge, A. D. de Langen +15 more
2022Journal of Clinical Oncology7 citations
Semantic Scholar
OA15.01 Mobocertinib in EGFR Exon 20 Insertion–Positive Metastatic NSCLC Patients With Disease Control on Prior EGFR TKI Therapy
A. Spira, S. Ramalingam, J. Neal, Z. Piotrowska +16 more
2021Journal of Thoracic Oncology7 citations Open access
Semantic Scholar
Clinical overview of trophoblast surface antigen 2 antibody-drug conjugates in non-small cell lung cancer.
S. Patel, S. Gadgeel, M. Mino-Kenudson, J. Naidoo +1 more
2025Cancer Treatment Reviews6 citations Open access
Semantic Scholar
A two-part, phase II, multi-center study of the ERK inhibitor ulixertinib (BVD-523) for patients with advanced malignancies harboring MEK or atypical BRAF alterations (BVD-523-ABC).
M. Burkard, M. McKean, Jordi Rodon Ahnert, N. Mettu +15 more
2022Journal of Clinical Oncology6 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

A. Spira×8
Invite
A. Spira — researcher profile on SciRah
E. Felip×8
Invite
E. Felip — researcher profile on SciRah
M. Johnson×6
Invite
M. Johnson — researcher profile on SciRah
J. Sabari×6
Invite
J. Sabari — researcher profile on SciRah

×6

Invite

E. Garon — researcher profile on SciRah

Gregory Riely×5

Invite

Gregory Riely — researcher profile on SciRah

L. Bazhenova×5

Invite

L. Bazhenova — researcher profile on SciRah

M. Garassino×5

Invite

M. Garassino — researcher profile on SciRah

Invite

M. Reck — researcher profile on SciRah

D. Rodríguez-Abreu×5

Invite

D. Rodríguez-Abreu — researcher profile on SciRah

Invite

D. Camidge — researcher profile on SciRah

Invite

D. Spigel — researcher profile on SciRah